= Emerging. More than 5 years before clinical availability. (16.60%, 2024)
= Expected to be clinically available in 1 to 4 years. (37.02%, 2024)
= Clinically available now. (46.38%, 2024)
MSACL 2024 : Eberlin

MSACL 2024 Abstract

Self-Classified Topic Area(s): Imaging > Imaging > none

Podium Presentation in De Anza 1 on Wednesday at 15:45 (Chair: Kristina Schwamborn / Hannah Brown)

Providing In Vivo Tissue Sensing Capabilities to Surgeons with the MasSpec Pen: Challenges and Opportunities

Livia Eberlin, PhD (Presenter)
Baylor College of Medicine

Presenter Bio: Dr. Eberlin received a bachelor’s in chemistry from the State University of Campinas in Sao Paulo, Brazil, and a Ph.D. in analytical chemistry from Purdue University. She went on to complete a research fellowship in the Department of Chemistry at Stanford University in California. Prior to joining Baylor College of Medicine, Dr. Eberlin was an assistant professor in the Departments of Chemistry, Oncology and Diagnostic Medicine at The University of Texas at Austin.

Dr. Eberlin and her research team are the recipients of many honors and awards for their scientific research, including a NIH/NCI K99/R00 Pathway to Independence Award, a Forbes 30 under 30 listing in the Healthcare category, a Moore Inventor Fellowship, and a MacArthur Fellowship in 2018. Her research group is funded by grants from the NIH, CPRIT and other research foundations. Additionally, Dr. Eberlin has published more than 80 peer-reviewed research articles in top-rated journals such as PNAS, Science Translational Medicine, Nature Communications, Cancer Research, and Clinical Chemistry.

Dr. Eberlin’s research program centers around the development and application of novel mass spectrometry technologies in health-related research, with a particular focus on disease detection and diagnosis to improve patient care and clinical outcomes.


Mass spectrometry techniques that allow direct and fast molecular analysis of clinical samples offer the exciting opportunity to incorporate molecular data into clinical practice to expedite clinical decision making and thus improve diagnosis and patient care. In this seminar, I will discuss developments and applications of the MasSpec Pen technology for clinical use, with emphasis on tissue sensing applications in the operating room. Key operational principles, depth of molecular data, and the analytical and diagnostic performance metrics achieved for tissue identification and disease detection will be discussed to provide a critical assessment of capabilities and potential uses within the context of routine clinical practice. My presentation will focus on results obtained in ongoing clinical studies in which surgeons are employing the MasSpec Pen Technology to guide clinical decision making. Challenges and opportunities in implementing the technology into clinical workflows will also be discussed.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: